Finoriq research workspace
Indaptus Therapeutics, Inc. (INDP) Historical Metrics
Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various. Review INDP valuation ratios, fundamentals, and filing metrics on Finoriq.
Company Snapshot
Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.
- Company
- Indaptus Therapeutics, Inc. (INDP)
- Ticker
- INDP
- Market Cap
- $327.1M
- Latest Price
- $2.455
- Industry
- Biotech & Pharma
Indaptus Therapeutics, Inc. (INDP) Current Valuation Metrics
Static valuation preview for Indaptus Therapeutics, Inc. (INDP). Market data retrieved 2026-07-09. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| Earnings YieldLatest TTM net income divided by market cap. | -6.2% | Net Income | TTM FY 2025 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -4.4% | Operating Cash Flow | TTM FY 2025 |
| Price / BookMarket cap divided by stockholders' equity. | 106x | Stockholders' Equity | FY 2025 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.